NeuroPace Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 3/6
NeuroPace şirketinin toplam hissedar öz sermayesi $11.9M ve toplam borcu $59.0M olup, bu da borç-öz sermaye oranını 496.6% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $97.0M ve $85.1M dir.
Anahtar bilgiler
496.63%
Borç/özkaynak oranı
US$59.01m
Borç
| Faiz karşılama oranı | n/a |
| Nakit | US$51.70m |
| Eşitlik | US$11.88m |
| Toplam yükümlülükler | US$85.11m |
| Toplam varlıklar | US$96.99m |
Son finansal sağlık güncellemeleri
Analiz Makalesi • Jan 09
NeuroPace (NASDAQ:NPCE) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • Jun 19
Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • Nov 07
Does NeuroPace (NASDAQ:NPCE) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • Apr 12
Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Recent updates
Analiz Makalesi • Jul 08
At US$17.80, Is It Time To Put NeuroPace, Inc. (NASDAQ:NPCE) On Your Watch List?
NeuroPace, Inc. ( NASDAQ:NPCE ), is not the largest company out there, but it saw a significant share price rise of 39...
Anlatı Güncellemesi • Jun 16
NPCE: Future Returns Will Reflect IGE Decision And RNS Execution Risk
Analysts have slightly raised their NeuroPace price expectations, with a key target moving to $20 from $19 as they factor in updated revenue guidance and ongoing strength in active prescribers, accounts, and the patient pipeline. Analyst Commentary Recent commentary around NeuroPace has centered on the updated 2026 revenue outlook of US$99 million to US$101 million for the core RNS business, which implies 21% to 23% growth, and on management’s comment that this guidance does not include any potential contribution from idiopathic generalized epilepsy expansion.
Anlatı Güncellemesi • Jun 02
NPCE: Strong Prescriber Momentum And 2026 Guidance Will Support More Optimistic Outlook
Narrative Update on NeuroPace The analyst price target for NeuroPace has moved from $19 to $20. Analysts point to stronger prescriber and patient pipeline trends and higher 2026 revenue guidance for the core RNS business as key drivers of this change.Analiz Makalesi • May 15
NeuroPace, Inc. (NASDAQ:NPCE) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
It's been a sad week for NeuroPace, Inc. ( NASDAQ:NPCE ), who've watched their investment drop 18% to US$15.79 in the...Anlatı Güncellemesi • Apr 30
NPCE: Future Returns Will Reflect Trial Data Strength And Execution Risk
Analysts have lifted their price target on NeuroPace from $15.63 to $18.00, citing updated expectations for revenue growth and profit margins, as well as a higher future P/E multiple following recent Street research coverage. Analyst Commentary The latest Street research on NeuroPace reflects constructive top line expectations alongside a watchful stance on execution and valuation risk.
Anlatı Güncellemesi • Apr 15
NPCE: Refreshed Growth Assumptions And Richer P E Outlook Will Support Upside
Analysts have increased their average price target on NeuroPace by $1, citing updated assumptions that include slightly stronger revenue growth, a revised discount rate, a lower projected profit margin and a higher future P/E multiple. Analyst Commentary Bullish analysts are highlighting NeuroPace as a name where recent research work has led to more constructive views on both execution and valuation.Anlatı Güncellemesi • Apr 01
NPCE: Higher Margin Conviction And Reaffirmed Guidance Will Support More Optimistic Outlook
Analysts have modestly increased their price target on NeuroPace by $1, citing refreshed assumptions around long term profit margins and a slightly higher future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts see room for long term margin improvement, which supports their willingness to apply a slightly higher future P/E multiple in their models.Anlatı Güncellemesi • Mar 17
NPCE: Expanded Epilepsy Indication And Guidance Reaffirmation Will Support More Optimistic Outlook
Analysts increased their price target on NeuroPace by about $0.45 to $19.88, citing updated assumptions around revenue growth, profit margins, the discount rate, and future P/E expectations. Analyst Commentary Bullish Takeaways Bullish analysts view the higher price target of about $19.88 as better aligned with their revised expectations for revenue growth and margin progress in the current model.Anlatı Güncellemesi • Mar 03
NPCE: Refined Risk And Margin Outlook Will Support Future Upside Potential
Analysts lifted their price target on NeuroPace by $1, citing updated assumptions around the discount rate, profit margin, and future P/E that refine how they view the company’s risk and earnings potential. Analyst Commentary Recent Street research points to a more constructive tone around NeuroPace, with bullish analysts fine tuning their models rather than making wholesale changes.Anlatı Güncellemesi • Feb 17
NPCE: Future Returns Will Reflect Trial Data Strength And Execution Risk
Analysts have raised their price target for NeuroPace by about $1 to approximately $16, reflecting updated assumptions around revenue growth, profit margins, and a lower future P/E multiple. Analyst Commentary Even with the roughly $1 move in the price target to about $16, some research commentary still reads as cautious rather than outright bullish.Anlatı Güncellemesi • Feb 03
NPCE: Updated Seizure Trial Data Will Support A More Optimistic Outlook
Analysts have nudged their price target on NeuroPace higher to about US$19.43 from roughly US$17.13, citing updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E that are consistent with recent Street research. Analyst Commentary Analysts updating their models around NeuroPace are using the revised price target to reflect refreshed assumptions on valuation, growth expectations, and execution risks rather than a wholesale change in thesis.Anlatı Güncellemesi • Jan 20
NPCE: Broader Epilepsy Indication And Trial Evidence Will Support Future Upside
Analysts now see NeuroPace as fairly valued around US$22.00 per share. They have made only slight tweaks to assumptions for discount rate, revenue growth, profit margin and future P/E, refining rather than overhauling their previous price target view.Analiz Makalesi • Jan 09
NeuroPace (NASDAQ:NPCE) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Anlatı Güncellemesi • Jan 06
NPCE: Expanded Epilepsy Indication And Trial Data Will Support Bullish Outlook
Analysts lifted their price target on NeuroPace from US$20.00 to US$22.00, citing changes in their fair value estimate along with updated assumptions for discount rate, revenue growth, profit margin and future P/E. What's in the News NeuroPace filed a Premarket Approval Supplement with the U.S. FDA to expand the labeled indication for its RNS System to antiseizure medication resistant idiopathic generalized epilepsy with generalized tonic clonic seizures, supported by preliminary NAUTILUS trial data showing a 77% median reduction in GTC seizures at 18 months and a favorable safety profile.Anlatı Güncellemesi • Dec 15
NPCE: Future Performance Will Reflect Trial Data Strength And Moderate Risk
Analysts have raised their price target on NeuroPace from 13.00 dollars to 15.00 dollars. This reflects modestly lower perceived risk, slightly stronger long term margin potential, and still supportive valuation multiples despite a tempered revenue growth outlook.Analiz Makalesi • Nov 19
Revenues Tell The Story For NeuroPace, Inc. (NASDAQ:NPCE) As Its Stock Soars 25%
Despite an already strong run, NeuroPace, Inc. ( NASDAQ:NPCE ) shares have been powering on, with a gain of 25% in the...Analiz Makalesi • Sep 19
NeuroPace, Inc. (NASDAQ:NPCE) Looks Just Right With A 25% Price Jump
Those holding NeuroPace, Inc. ( NASDAQ:NPCE ) shares would be relieved that the share price has rebounded 25% in the...Analiz Makalesi • Aug 14
NeuroPace, Inc. (NASDAQ:NPCE) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
NasdaqGM:NPCE 1 Year Share Price vs Fair Value Explore NeuroPace's Fair Values from the Community and select yours...Seeking Alpha • Jun 29
NeuroPace: Volatile, Uncertain, But Promising
Summary NeuroPace has shown strong sales growth in its core drug-resistant epilepsy market, but remains unprofitable due to ongoing R&D expenses. Recent topline momentum is impressive, with 2024 guidance raised and sales growth accelerating, yet operating losses have stopped narrowing and even increased. The NAUTILUS trial failed to meet primary endpoints for generalized epilepsy, a major setback that limits near-term market expansion potential. Despite a reasonable sales multiple and recent financing, the failed trial and persistent losses make me cautious and hesitant to increase my position. Read the full article on Seeking AlphaAnaliz Makalesi • Jun 19
Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • May 13
NeuroPace, Inc. (NASDAQ:NPCE) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
NeuroPace, Inc. ( NASDAQ:NPCE ) shareholders would be excited to see that the share price has had a great month...
Yeni Anlatı • Mar 30
Expanding Level 4 Epilepsy Centers Will Unlock Future Potential
Expanding presence in epilepsy centers and Project CARE may significantly boost revenue by increasing market penetration and service delivery.Analiz Makalesi • Mar 07
NeuroPace, Inc. (NASDAQ:NPCE) Annual Results: Here's What Analysts Are Forecasting For This Year
It's been a sad week for NeuroPace, Inc. ( NASDAQ:NPCE ), who've watched their investment drop 11% to US$11.18 in the...Analiz Makalesi • Jan 24
NeuroPace, Inc. (NASDAQ:NPCE) Looks Just Right With A 26% Price Jump
Despite an already strong run, NeuroPace, Inc. ( NASDAQ:NPCE ) shares have been powering on, with a gain of 26% in the...Analiz Makalesi • Dec 04
After Leaping 90% NeuroPace, Inc. (NASDAQ:NPCE) Shares Are Not Flying Under The Radar
NeuroPace, Inc. ( NASDAQ:NPCE ) shares have had a really impressive month, gaining 90% after a shaky period beforehand...Analiz Makalesi • Nov 14
Here's What Analysts Are Forecasting For NeuroPace, Inc. (NASDAQ:NPCE) After Its Third-Quarter Results
A week ago, NeuroPace, Inc. ( NASDAQ:NPCE ) came out with a strong set of quarterly numbers that could potentially lead...Analiz Makalesi • Nov 07
Does NeuroPace (NASDAQ:NPCE) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • Aug 03
NeuroPace, Inc. (NASDAQ:NPCE) Screens Well But There Might Be A Catch
It's not a stretch to say that NeuroPace, Inc.'s ( NASDAQ:NPCE ) price-to-sales (or "P/S") ratio of 2.9x right now...Analiz Makalesi • Apr 12
Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Feb 25
NeuroPace: Picking Up The Pace
Summary NeuroPace shares have doubled since September 2023, driven by strong operating momentum. The company aims to improve the lives of epilepsy patients with its remote monitoring system, which has the potential for significant growth. Following the share price rally, I have trimmed my position but continue to hold a long position due to the company's potential and operating momentum. Read the full article on Seeking AlphaAnaliz Makalesi • Jan 22
Why Investors Shouldn't Be Surprised By NeuroPace, Inc.'s (NASDAQ:NPCE) 58% Share Price Surge
Despite an already strong run, NeuroPace, Inc. ( NASDAQ:NPCE ) shares have been powering on, with a gain of 58% in the...Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: NPCE 'nin kısa vadeli varlıkları ( $86.2M ) kısa vadeli yükümlülüklerini ( $17.4M ) aşıyor.
Uzun Vadeli Yükümlülükler: NPCE şirketinin kısa vadeli varlıkları ( $86.2M ) uzun vadeli yükümlülüklerini ( $67.7M ) aşmaktadır.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: NPCE 'nin net borç/öz sermaye oranı ( 61.6% ) yüksek olarak değerlendiriliyor.
Borcun Azaltılması: NPCE şirketinin borç/öz sermaye oranı son 5 yılda 55.7% seviyesinden 496.6% seviyesine yükseldi.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: NPCE şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.
Tahmini Nakit Akışı: NPCE tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.
Sağlıklı şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/23 12:31 |
| Gün Sonu Hisse Fiyatı | 2026/08/21 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
NeuroPace, Inc. 14 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Michael Polark | Baird |
| Sarah James | Cantor Fitzgerald & Co. |
| Ross Osborn | Cantor Fitzgerald & Co. |